An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Phase 1

Recruiting

Interventions: Procedure: Magnetic Resonance Imaging
Drug: Hyperpolarized Carbon C 13 Pyruvate

Brief Summary: This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.

Detailed Description: PRIMARY OBJECTIVE:

I. To obtain pilot metabolic imaging data from hyperpolarized magnetic resonance imaging (hpMRI) methods in patients with thyroid tumors or other malignancies of the head and neck receiving radiation therapy (XRT) and/or systemic therapy (e.g., target therapy, checkpoint inhibitors).

SECONDARY OBJECTIVE:

I. To assess early metabolic changes in response to nonsurgical therapy, including standard-of-care fractionated XRT and/or systemic therapy.

OUTLINE: Participants are assigned to 1 of 2 arms.

ARM I: Healthy volunteers undergo MRI over 30 minutes.

ARM II: Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate intravenously (IV) over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.

After completion of study intervention, thyroid cancer and other malignancies of the head and neck patients are followed up at 1 day.

Recruitment & Eligibility

Inclusion Criteria

Be willing and able to provide informed consent
Be informed of the investigational nature of this study
Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment

Exclusion Criteria

Have a history of severe claustrophobia
Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI)
Have a history of cardiac arrhythmia
Have an allergy to Gadavist intravenous contrast
Estimated glomerular filtration rate (eGFR) < 30
If female, be pregnant or breast feeding at time of consent

Arm && Interventions

Group	Intervention	Description
Arm I ( Health Volunteer MRI)	Magnetic Resonance Imaging	Healthy volunteers undergo MRI over 30 minutes.
Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)	Hyperpolarized Carbon C 13 Pyruvate	Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)	Magnetic Resonance Imaging	Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.

Primary Outcome Measures

Name	Time	Method
Metabolic imaging data from hyperpolarized magnetic resonance imaging (hpMRI) methods	1 year	To measure metabolic imaging data or information derived from hyperpolarized pyruvate MRI (hpMRI) that can be used to identify an early indication of response to therapy in patients with thyroid cancer. Specifically, we measure the kPL-the apparent rate constant for conversion of HP pyruvate into lactate-after one week of treatment compared to baseline measurements acquired prior to start of therapy. The kPL will be calculated from dynamic images of HP pyruvate and its metabolites. The kPL values will be calculated for each tumor and its adjacent tissue by a radiologist and physicist in conjunction using region of interest analysis to identify the margins of the tumor and surrounding normal tissue.

Secondary Outcome Measures

Name	Time	Method
Early metabolic changes	1 year	To assess early metabolic changes in response to nonsurgical therapy, including standard-of-care fractionated XRT and/or systemic therapy. The imaging biomarker for tumor metabolism, kPL, will be calculated from dynamic images of HP pyruvate and its metabolites.